Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,410 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02177812 | A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML) | terminated | Phase 1 | 41 | GlaxoSmithKlineINDUSTRY | 3 | Jun 28, 2019 | clinicaltrials |
| NCT00235482 | Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02)(PXS-X02) | completed | Phase 1 | 3 | ViralyticsINDUSTRY | 1 | Jun 27, 2019 | clinicaltrials |
| NCT01212107 | A Phase 1 Study of LY2874455 in Participants With Advanced Cancer | completed | Phase 1 | 94 | Eli Lilly and CompanyINDUSTRY | 2 | Jun 12, 2019 | clinicaltrials |
| NCT02920541 | Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome | completed | Phase 1 | 48 | Institut de Recherches Internationales ServierOTHER | 2 | May 24, 2019 | clinicaltrials |
| NCT02306291 | Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML | completed | Phase 1 / Phase 2 | 91 | GlycoMimetics IncorporatedINDUSTRY | 3 | May 17, 2019 | clinicaltrials |
| NCT00858377 | A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors | completed | Phase 1 | 95 | AmgenINDUSTRY | 2 | May 6, 2019 | clinicaltrials |
| NCT02341456 | Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours | completed | Phase 1 | 19 | AstraZenecaINDUSTRY | 3 | Mar 25, 2019 | clinicaltrials |
| NCT01231594 | A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors | completed | Phase 1 | 214 | Novartis PharmaceuticalsINDUSTRY | 9 | Mar 22, 2019 | clinicaltrials |
| NCT01283516 | A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase | completed | Phase 1 | 304 | Novartis PharmaceuticalsINDUSTRY | 11 | Mar 15, 2019 | clinicaltrials |
| NCT02221960 | A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors | completed | Phase 1 | 39 | MedImmune LLCINDUSTRY | 2 | Mar 13, 2019 | clinicaltrials |
| NCT02189109 | The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma(GBM) | completed | Phase 1 | 11 | NuvOx LLCINDUSTRY | 1 | Feb 28, 2019 | clinicaltrials |
| NCT02688101 | Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors | completed | Phase 1 | 14 | Collaborative Medicinal Development Pty LimitedINDUSTRY | 1 | Feb 21, 2019 | clinicaltrials |
| NCT02129556 | Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer(PANACEA) | completed | Phase 1 / Phase 2 | 58 | ETOP IBCSG Partners FoundationNETWORK | 5 | Feb 15, 2019 | clinicaltrials |
| NCT03202992 | Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection | completed | Phase 1 | 57 | Antiva BiosciencesINDUSTRY | 2 | Feb 7, 2019 | clinicaltrials |
| NCT02726334 | A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer. | terminated | Phase 1 | 22 | Bionomics LimitedINDUSTRY | 1 | Jan 16, 2019 | clinicaltrials |
| NCT01292603 | A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia | completed | Phase 1 | 240 | Hoffmann-La RocheINDUSTRY | 19 | Dec 19, 2018 | clinicaltrials |
| NCT02966171 | A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies | terminated | Phase 1 | 14 | Hutchison Medipharma LimitedINDUSTRY | 1 | Nov 21, 2018 | clinicaltrials |
| NCT03736122 | A Study of Syngenon (BSG-001) for Inhalation in Subjects With Malignant Pleural Effusion and/or Malignant Ascites | unknown | Phase 1 / Phase 2 | 58 | BioSyngen Pte LtdINDUSTRY | 1 | Nov 8, 2018 | clinicaltrials |
| NCT01801111 | A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment | completed | Phase 1 / Phase 2 | 138 | Hoffmann-La RocheINDUSTRY | 16 | Nov 2, 2018 | clinicaltrials |
| NCT00982865 | Trial of MSC1936369B in Subjects With Solid Tumors | completed | Phase 1 | 182 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 4 | Oct 23, 2018 | clinicaltrials |
| NCT00231166 | Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma | completed | Phase 1 | 33 | Novartis PharmaceuticalsINDUSTRY | 2 | Oct 11, 2018 | clinicaltrials |
| NCT00741260 | Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer | completed | Phase 1 / Phase 2 | 105 | Puma Biotechnology, Inc.INDUSTRY | 11 | Sep 5, 2018 | clinicaltrials |
| NCT01950273 | Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma | completed | Phase 1 | 95 | Boehringer IngelheimINDUSTRY | 13 | Sep 5, 2018 | clinicaltrials |
| NCT01428492 | Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma(PKB115125) | completed | Phase 1 | 90 | NovartisINDUSTRY | 5 | Aug 8, 2018 | clinicaltrials |
| NCT02550678 | A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma(ASN-002-001) | completed | Phase 1 / Phase 2 | 16 | Ascend Biopharmaceuticals LtdINDUSTRY | 1 | Jun 6, 2018 | clinicaltrials |
| NCT03529526 | Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Antitumor Activity of KN046 in Subjects With Advanced Solid Tumors | unknown | Phase 1 | 21 | Alphamab (Australia) Co Pty Ltd.INDUSTRY | 1 | May 22, 2018 | clinicaltrials |
| NCT02657330 | Study of SBP-101 in Pancreatic Cancer | completed | Phase 1 | 29 | Panbela Therapeutics, Inc.INDUSTRY | 2 | Apr 20, 2018 | clinicaltrials |
| NCT01653912 | Dose-finding Study in Platinum-Resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 59 | AccentureINDUSTRY | 3 | Apr 2, 2018 | clinicaltrials |
| NCT00299494 | Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL) | completed | Phase 1 / Phase 2 | 119 | PfizerINDUSTRY | 13 | Mar 8, 2018 | clinicaltrials |
| NCT00707707 | Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer | completed | Phase 1 | 19 | AstraZenecaINDUSTRY | 4 | Mar 6, 2018 | clinicaltrials |
| NCT01767623 | A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants | completed | Phase 1 | 8 | Hoffmann-La RocheINDUSTRY | 7 | Feb 13, 2018 | clinicaltrials |
| NCT00098839 | Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) | completed | Phase 1 / Phase 2 | 134 | Children's Oncology GroupNETWORK | 4 | Dec 12, 2017 | clinicaltrials |
| NCT00629473 | Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies | completed | Phase 1 | 86 | CelgeneINDUSTRY | 1 | Nov 22, 2017 | clinicaltrials |
| NCT00667082 | NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma | completed | Phase 1 | 22 | CelgeneINDUSTRY | 1 | Nov 22, 2017 | clinicaltrials |
| NCT02103335 | Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma | completed | Phase 1 | 38 | CelgeneINDUSTRY | 2 | Nov 22, 2017 | clinicaltrials |
| NCT01589419 | A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer | completed | Phase 1 | 32 | AbbVie (prior sponsor, Abbott)INDUSTRY | 2 | Nov 20, 2017 | clinicaltrials |
| NCT01954043 | A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors | completed | Phase 1 | 23 | GlaxoSmithKlineINDUSTRY | 3 | Nov 14, 2017 | clinicaltrials |
| NCT00880321 | A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors | completed | Phase 1 | 170 | GlaxoSmithKlineINDUSTRY | 2 | Nov 13, 2017 | clinicaltrials |
| NCT01110031 | Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects | completed | Phase 1 | 12 | GlaxoSmithKlineINDUSTRY | 3 | Nov 13, 2017 | clinicaltrials |
| NCT01738451 | A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors | completed | Phase 1 | 50 | GlaxoSmithKlineINDUSTRY | 3 | Nov 13, 2017 | clinicaltrials |
| NCT01827644 | Bioavailability and Food Effect of the Original Gelatin Formulation and Two New Formulations of Afuresertib in Normal Healthy Volunteers | completed | Phase 1 | 36 | GlaxoSmithKlineINDUSTRY | 1 | Nov 13, 2017 | clinicaltrials |
| NCT02040480 | Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib | completed | Phase 1 | 18 | GlaxoSmithKlineINDUSTRY | 1 | Nov 13, 2017 | clinicaltrials |
| NCT01139138 | Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer(PIE) | completed | Phase 1 / Phase 2 | 49 | The Queen Elizabeth HospitalOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT02303366 | Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475(BOSTON II) | completed | Phase 1 | 15 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Oct 18, 2017 | clinicaltrials |
| NCT01252095 | Study of the Safety and Tolerability of PG545 in Patients With Advanced Solid Tumours | terminated | Phase 1 | 4 | Zucero Pty LtdINDUSTRY | 1 | Oct 9, 2017 | clinicaltrials |
| NCT02042781 | Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours | completed | Phase 1 | 23 | Zucero Pty LtdINDUSTRY | 1 | Oct 9, 2017 | clinicaltrials |
| NCT02278133 | Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations | completed | Phase 1 / Phase 2 | 20 | Array BioPharmaINDUSTRY | 10 | Oct 9, 2017 | clinicaltrials |
| NCT01449058 | A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors | completed | Phase 1 | 139 | Array BioPharmaINDUSTRY | 7 | Oct 2, 2017 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials